Assenagon Asset Management S.A. Has $23.65 Million Position in uniQure N.V. $QURE

Key Points

• Assenagon Asset Management increased its uniQure position by 249.9% in the second quarter, acquiring 366,781 additional shares. Its holding totaled 513,530 shares worth approximately $23.65 million, while institutional investors owned 78.83% of QURE.
• Analyst sentiment was broadly positive, with a consensus “Moderate Buy” rating and an average price target of $65. Price targets ranged from $46 to $80, although some firms maintained or issued sell ratings.
• uniQure reported a quarterly loss of $1.22 per share, missing estimates of $0.82, despite revenue of $5.84 million exceeding expectations. The stock opened at $46.42, after trading between $8.73 and $71.50 over the past year, while insiders sold roughly $16.8 million of shares during the previous 90 days.

Assenagon Asset Management S.A. raised its position in uniQure N.V. (NASDAQ:QURE - Free Report) by 249.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 513,530 shares of the biotechnology company's stock after purchasing an additional 366,781 shares during the period. Assenagon Asset Management S.A. owned approximately 0.81% of uniQure worth $23,653,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Torren Management LLC acquired a new position in shares of uniQure in the 4th quarter valued at $28,000. IFP Advisors Inc acquired a new stake in shares of uniQure during the fourth quarter worth about $48,000. Smartleaf Asset Management LLC bought a new position in shares of uniQure during the 4th quarter valued at about $48,000. CIBC Private Wealth Group LLC bought a new position in shares of uniQure during the 3rd quarter valued at about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of uniQure by 42.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company's stock valued at $72,000 after purchasing an additional 906 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Mizuho increased their target price on uniQure from $35.00 to $68.00 and gave the stock an "outperform" rating in a research note on Thursday, June 25th. HC Wainwright lifted their price target on shares of uniQure from $50.00 to $80.00 and gave the company a "buy" rating in a research note on Monday, June 29th. The Goldman Sachs Group upped their price target on shares of uniQure from $14.00 to $46.00 and gave the company a "neutral" rating in a report on Thursday, June 18th. Wall Street Zen cut shares of uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, August 1st. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of uniQure in a research note on Friday, June 26th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $65.00.

uniQure Stock Performance

uniQure stock opened at $46.42 on Monday. The company has a market cap of $3.22 billion, a price-to-earnings ratio of -11.58 and a beta of 0.93. The firm has a 50-day moving average of $39.41 and a 200-day moving average of $27.07. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The company had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same quarter in the prior year, the business earned ($0.69) earnings per share. On average, equities analysts expect that uniQure N.V. will post -3.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other uniQure news, Director Madhavan Balachandran sold 11,685 shares of the company's stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total value of $526,526.10. Following the transaction, the director directly owned 43,254 shares in the company, valued at $1,949,025.24. The trade was a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total transaction of $982,995.48. Following the completion of the transaction, the director directly owned 25,996 shares in the company, valued at $1,207,254.24. The trade was a 44.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 388,229 shares of company stock worth $16,817,099. Company insiders own 4.65% of the company's stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source